These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 1572039

  • 41. Effects of simvastatin on cigarette smoke extract induced tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in human umbilical vein endothelial cells.
    Hu XY, Ma YH, Wang C, Yang YH.
    Chin Med J (Engl); 2009 Oct 05; 122(19):2380-5. PubMed ID: 20079143
    [Abstract] [Full Text] [Related]

  • 42. [Hypofibrinolysis after venous occlusion in patients treated with long-term hemodialysis].
    Opatrný K, Vít L, Opatrná S, Sulková S, Bodláková B.
    Cas Lek Cesk; 1994 May 30; 133(11):346-9. PubMed ID: 8004664
    [Abstract] [Full Text] [Related]

  • 43. Changes in plasma levels of tissue-plasminogen activator/inhibitor complex and active plasminogen activator inhibitor in patients with disseminated intravascular coagulation.
    Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Matsuda T.
    Am J Hematol; 1991 Mar 30; 36(3):176-83. PubMed ID: 1899963
    [Abstract] [Full Text] [Related]

  • 44. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
    Ferguson JW, Helmy A, Ludlam C, Webb DJ, Hayes PC, Newby DC.
    Thromb Res; 2008 Mar 30; 121(5):675-80. PubMed ID: 17870147
    [Abstract] [Full Text] [Related]

  • 45. Time dependent release of tissue-type plasminogen activator and plasminogen activator inhibitor into the circulation of pigs during shock.
    Siebeck M, Spannagl M, Hoffmann H, Schramm W, Fritz H.
    Blood Coagul Fibrinolysis; 1991 Jun 30; 2(3):459-64. PubMed ID: 1834237
    [Abstract] [Full Text] [Related]

  • 46. Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies.
    Colucci M, Altomare DF, Chetta G, Triggiani R, Cavallo LG, Semeraro N.
    Thromb Haemost; 1988 Aug 30; 60(1):25-9. PubMed ID: 3142090
    [Abstract] [Full Text] [Related]

  • 47. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D, Kremplewska-Nalezyta E, Gadomska G, Zastawna E, Michalski A, Drewniak W.
    Med Sci Monit; 2000 Aug 30; 6(4):684-91. PubMed ID: 11208392
    [Abstract] [Full Text] [Related]

  • 48. The relationship between cardiovascular complications of estrogen therapy and fibrinolysis in patients with prostatic cancer.
    Hasui Y, Marutsuka K, Nishi S, Kitada S, Osada Y, Sumiyoshi A.
    Prostate; 1992 Aug 30; 21(1):35-9. PubMed ID: 1641370
    [Abstract] [Full Text] [Related]

  • 49. Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma.
    Alessi MC, Juhan-Vague I, Declerck PJ, Collen D.
    Thromb Res; 1991 May 15; 62(4):275-85. PubMed ID: 1907771
    [Abstract] [Full Text] [Related]

  • 50. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation.
    Brommer EJ, Dooijewaard G, Dijkmans BA, Breedveld FC.
    Thromb Haemost; 1992 Aug 03; 68(2):180-4. PubMed ID: 1412164
    [Abstract] [Full Text] [Related]

  • 51. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
    Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR.
    Blood; 2010 Jul 08; 116(1):113-21. PubMed ID: 20385790
    [Abstract] [Full Text] [Related]

  • 52. Plasminogen activator inhibitor-1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism.
    Reilly CF, Fujita T, Hutzelmann JE, Mayer EJ, Shebuski RJ.
    Circulation; 1991 Jul 08; 84(1):287-92. PubMed ID: 1905594
    [Abstract] [Full Text] [Related]

  • 53. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1.
    Urano T, Sakakibara K, Rydzewski A, Urano S, Takada Y, Takada A.
    Thromb Haemost; 1990 Feb 19; 63(1):82-6. PubMed ID: 2111051
    [Abstract] [Full Text] [Related]

  • 54. Fibrinolytic response in normal subjects to venous occlusion and DDAVP infusion.
    Cugno M, Uziel L, Fabrizi I, Bottasso B, Maggiolini F, Agostoni A.
    Thromb Res; 1989 Dec 01; 56(5):625-34. PubMed ID: 2516662
    [Abstract] [Full Text] [Related]

  • 55. Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels.
    Alessi MC, Juhan-Vague I, Declerck PJ, Anfosso F, Gueunoun E, Collen D.
    Thromb Res; 1990 Dec 15; 60(6):509-16. PubMed ID: 2127964
    [No Abstract] [Full Text] [Related]

  • 56. The fibrinolytic system in chronic renal failure.
    Lottermoser K, Petras S, Pöge U, Fimmers R, Hertfelder HJ, Schiermeyer B, Vetter H, Düsing R.
    Eur J Med Res; 2001 Sep 28; 6(9):372-6. PubMed ID: 11591527
    [Abstract] [Full Text] [Related]

  • 57. Increased plasminogen activator inhibitor results in a hypofibrinolytic state in adolescents with obesity: in vivo and ex vivo evidence.
    Dietrich K, Ball GD, Mitchell LG.
    Br J Haematol; 2016 Oct 28; 175(2):300-307. PubMed ID: 27434823
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Tissue-type plasminogen activator and plasminogen activator inhibitor activities as predictors of adverse events in unstable angina.
    Wieczorek I, Ludlam CA, Fox KA.
    Am J Cardiol; 1994 Sep 01; 74(5):424-9. PubMed ID: 8059719
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.